Antimicrobial and anti-inflammatory treatment of bacterial meningitis.
Mortality and morbidity rates of bacterial meningitis are still unacceptably high, and thus, new, potent antimicrobial agents and adjuvant anti-inflammatory strategies are being evaluated to improve patient outcome. With the declining rates of Haemophilus influenzae type B infections, after the introduction of conjugated vaccines, research to find preventive measures for Streptococcus pneumoniae and Neisseria meningitidis infections is underway. In the meantime, scientific effort is being directed optimally to treat disease caused by multiresistant pneumococcal strains.
Sáez-Llorens
X
X
Department of Pediatrics, University of Panama School of Medicine, Panama City, Panama. xsaez@panama.phoenix.net
McCracken
G H
GH
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003907:Dexamethasone / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006192:Haemophilus Infections / Q000188:drug therapy / Q000382:microbiology; D019741:Haemophilus influenzae type b; D006801:Humans; D016920:Meningitis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D008585:Meningitis, Meningococcal / Q000188:drug therapy / Q000382:microbiology; D009345:Neisseria meningitidis; D017410:Practice Guidelines as Topic; D013296:Streptococcus pneumoniae
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D003907:Dexamethasone